David Marin , Dragana Milojkovic , Marco Bua , Hugues de Lavallade , Catharina Andreasson , Priscilla R. Sauramba , Julia Nicol , Nuria Gonzalez-Cinca , John M. Goldman , Jane F. Apperley
{"title":"达沙替尼在慢性髓系白血病中的应用:一些实际考虑","authors":"David Marin , Dragana Milojkovic , Marco Bua , Hugues de Lavallade , Catharina Andreasson , Priscilla R. Sauramba , Julia Nicol , Nuria Gonzalez-Cinca , John M. Goldman , Jane F. Apperley","doi":"10.3816/CLK.2007.n.013","DOIUrl":null,"url":null,"abstract":"Abstract The new multitargeted tyrosine kinase inhibitor dasatinib has been used for 2 years in the treatment of patients with chronic myeloid leukemia whose disease has not responded to or has relapsed on imatinib or who are intolerant of the drug. Dasatinib has proven to be highly effective in re-establishing cytogenetic and/or molecular remissions in patients in all phases of chronic myeloid leukemia resistant to imatinib. The principal side effects include myelosuppression and the development of pleural effusions, both of which can be managed successfully by reduction in dosage or temporary interruption of the drug. Dasatinib could play an important role in the management of newly diagnosed patients, especially those who present with advanced-phase disease.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"1 4","pages":"Pages 229-233"},"PeriodicalIF":0.0000,"publicationDate":"2007-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2007.n.013","citationCount":"8","resultStr":"{\"title\":\"The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations\",\"authors\":\"David Marin , Dragana Milojkovic , Marco Bua , Hugues de Lavallade , Catharina Andreasson , Priscilla R. Sauramba , Julia Nicol , Nuria Gonzalez-Cinca , John M. Goldman , Jane F. Apperley\",\"doi\":\"10.3816/CLK.2007.n.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The new multitargeted tyrosine kinase inhibitor dasatinib has been used for 2 years in the treatment of patients with chronic myeloid leukemia whose disease has not responded to or has relapsed on imatinib or who are intolerant of the drug. Dasatinib has proven to be highly effective in re-establishing cytogenetic and/or molecular remissions in patients in all phases of chronic myeloid leukemia resistant to imatinib. The principal side effects include myelosuppression and the development of pleural effusions, both of which can be managed successfully by reduction in dosage or temporary interruption of the drug. Dasatinib could play an important role in the management of newly diagnosed patients, especially those who present with advanced-phase disease.\",\"PeriodicalId\":100271,\"journal\":{\"name\":\"Clinical Leukemia\",\"volume\":\"1 4\",\"pages\":\"Pages 229-233\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3816/CLK.2007.n.013\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1931692513600650\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931692513600650","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations
Abstract The new multitargeted tyrosine kinase inhibitor dasatinib has been used for 2 years in the treatment of patients with chronic myeloid leukemia whose disease has not responded to or has relapsed on imatinib or who are intolerant of the drug. Dasatinib has proven to be highly effective in re-establishing cytogenetic and/or molecular remissions in patients in all phases of chronic myeloid leukemia resistant to imatinib. The principal side effects include myelosuppression and the development of pleural effusions, both of which can be managed successfully by reduction in dosage or temporary interruption of the drug. Dasatinib could play an important role in the management of newly diagnosed patients, especially those who present with advanced-phase disease.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
